Data from a phase II clinical trial using ribociclib and letrozole to treat hormone +, HER2− BC patients showed a reduction in Ki-67 expression, phosphorylated Rb concentrations, and reduced the gene expression of CDK4, CDK6, cyclin D2, cyclin D3, and cyclin E1 [126]. The gene discussed is CDK4; the disease is breast cancer.